Mereo BioPharma director granted new equity awards

Jenkins Annalisa reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Jenkins Annalisa reported acquisition or exercise transactions in this Form 4 filing.

Mereo BioPharma Group director Annalisa Jenkins received new equity-based compensation awards. She was granted 66,000 share options with a right to buy shares at no initial cost and 106,848 deferred restricted stock units, both dated February 26, 2026.

The share options vest in substantially equal monthly installments over one year from the grant date. The deferred restricted stock units were elected in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after service ends.

Insider Trade Summary

Grant/Award: 172,848 shares

Grant/Award 2 txns

Insider Jenkins Annalisa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Options (Right to buy)	66,000	$0.00	$0.00
Grant/Award	Deferred Restricted Stock Units	106,848	$0.00	$0.00

Holdings After Transaction: Share Options (Right to buy) — 66,000 contracts (Direct); Deferred Restricted Stock Units — 106,848 contracts (Direct)

Footnotes (3)

1. F1. Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
2. F2. Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
3. F3. Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mereo BioPharma (MREO) report for Annalisa Jenkins?

Mereo BioPharma reported that director Annalisa Jenkins received 66,000 share options and 106,848 deferred restricted stock units on February 26, 2026. Both awards are part of her equity-based director compensation package.

How many share options were granted to director Annalisa Jenkins at Mereo BioPharma (MREO)?

Director Annalisa Jenkins was granted 66,000 share options with a right to buy shares at a price shown as zero. These options vest in substantially equal monthly installments over a one-year period from the February 26, 2026 grant date.

What are the details of the deferred restricted stock units granted to Annalisa Jenkins at Mereo BioPharma (MREO)?

Annalisa Jenkins received 106,848 deferred restricted stock units as a director. These units were granted in lieu of annual cash compensation, vest in substantially equal monthly installments over the plan year, and are generally paid in ADSs about 180 days after service ends.

How do Mereo BioPharma (MREO) deferred restricted stock units for directors work?

Deferred restricted stock units are granted to non-executive directors who elect ADS-based awards instead of cash fees. They vest in substantially equal monthly installments over the plan year and are generally settled in ADSs approximately 180 days after a director’s separation of service.

What does each Mereo BioPharma (MREO) ADS represent in ordinary shares?

Each Mereo BioPharma American Depositary Share (ADS) represents five ordinary shares of the issuer, each with a nominal value of GBP 0.003 per ordinary share. This ratio applies to settlement of the deferred restricted stock units in ADS form.

Is Annalisa Jenkins’ Form 4 transaction at Mereo BioPharma (MREO) a purchase or a grant?

The Form 4 transactions for Annalisa Jenkins reflect grant or award acquisitions, not open-market purchases. She acquired share options and deferred restricted stock units as compensation, both reported with transaction code A for award or other acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jenkins Annalisa

(Last) (First) (Middle)

C/O MEREO BIOPHARMA GROUP PLC

4TH FLOOR, ONE CAVENDISH PLACE

(Street)

LONDON X0 W1G 0QF

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mereo BioPharma Group plc [ MREO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Options (Right to buy)	$0.39	02/26/2026		A		66,000		(1)	02/26/2036	American Depositary Shares(2)	66,000	$0	66,000	D
Deferred Restricted Stock Units	(3)	02/26/2026		A		106,848		(3)	(3)	American Depository Shares(2)	106,848	(3)	106,848	D

Explanation of Responses:

1. Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.

2. Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

3. Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.

	/s/ Christine Fox, by power of attorney	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.